SSSebastian Sanchez

Sebastian Sanchez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sebastian Sanchez has a total of 220 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Factors Associated With Stroke Recurrence After Initial Diagnosis of Cervical Artery Dissection

    by Daniel M. Mandel, Liqi Shu, Christopher Chang, Naomi Jack, Christopher R. Leon Guerrero, Nils Henninger, Jayachandra Muppa, Muhammad Affan, Omair Ul Haq Lodhi, Mirjam R. Heldner, et al.

    BACKGROUND: Patients presenting with cervical artery dissection (CAD) are at risk for subsequent ischemic events. We aimed to identify characteristics that are associated with increased risk of ischemic stroke after initial presentation of CAD and to evaluate the differential impact of anticoagulant versus antiplatelet therapy in these high-risk individuals. METHODS: This was a preplanned secondary analysis of the STOP-CAD study (Antithrombotic Treatment for Stroke Prevention in Cervical Artery Dissection), a multicenter international retrospective observational study (63 sites from 16 countries in North America, South America, Europe, Asia, and Africa) that included patients with CAD predominantly between January 2015 and June 2022. The primary outcome was subsequent ischemic stroke by day 180 after diagnosis. Clinical and imaging variables were compared between those with versus without subsequent ischemic stroke. Significant factors associated with subsequent stroke risk were identified using stepwise Cox regression. Associations between subsequent ischemic stroke risk and antithrombotic therapy type (anticoagulation versus antiplatelets) among patients with identified risk factors were explored using adjusted Cox regression. RESULTS: In all, 4023 patients (mean age was 47.4 years; 44.5% were women) were included. By day 180, subsequent ischemic stroke occurred in 5.3% of the cohort. In adjusted Cox regression, factors associated with increased risk of subsequent ischemic stroke were prior history of ischemic stroke (adjusted hazard ratio [aHR], 7.31 [95% CI, 1.61–33.13]; P =0.010), presentation within 7 days from first symptoms (aHR, 3.04 [95% CI, 1.04–8.91]; P =0.043), infarct on baseline imaging (aHR, 9.85 [95% CI, 3.65–26.58]; P P =0.043). Only patients with occlusive dissection demonstrated a reduced risk of subsequent ischemic stroke when treated with anticoagulation versus antiplatelets (aHR, 0.36 [95% CI, 0.16–0.80]; P =0.01). CONCLUSIONS: In this post hoc analysis of the STOP-CAD study, several factors associated with subsequent ischemic stroke were identified among patients with CAD. Furthermore, we identified a potential benefit of anticoagulation in patients with CAD with occlusive dissection. These findings require validation by meta-analyses of prior studies to formulate optimal treatment strategies for specific high-risk CAD subgroups.


  • Open Access

    Predictors of Stroke Recurrence After Initial Diagnosis of Cervical Artery Dissection

    by Daniel M. Mandel, Liqi Shu, Christopher Chang, Naomi Jack, Christopher R. Leon Guerrero, Nils Henninger, Jayachandra Muppa, Muhammad Affan, Omair Ul Haq Lodhi, Mirjam R. Heldner, et al.

    Objective Patients with cervical artery dissection (CAD) are at increased ischemic stroke risk. We aimed to identify characteristics that are associated with increased risk of ischemic stroke following initial presentation of CAD and to evaluate the differential impact of anticoagulant versus antiplatelet therapy in these high-risk individuals. Methods This was a secondary analysis of the Antithrombotic Treatment for Stroke Prevention in Cervical Artery Dissection (STOP-CAD) study, a multicenter retrospective observational study. The primary outcome was subsequent ischemic stroke by day 180 after diagnosis. Patient characteristics were compared between those with vs. without subsequent ischemic stroke. Significant predictors were identified using stepwise Cox regression. Associations between subsequent ischemic stroke risk and antithrombotic therapy type in high-risk patients were explored using adjusted Cox regression. Results 4,023 patients (mean age 47.4 years; 44.5% were women) were included. By day 180, 5.3% experienced a subsequent ischemic stroke. In adjusted Cox regression, factors associated with increased subsequent ischemic stroke risk were prior ischemic stroke (aHR 7.31, 95% CI 1.61-33.13, p=0.010), presentation within seven days from symptoms, (aHR 3.04, 95% CI 1.04-8.91, p=0.043), infarct on imaging (aHR 9.85, 95% CI 3.65-26.58, pInterpretation This study identified several predictors of subsequent ischemic stroke among patients with CAD but only patients with occlusive dissection demonstrated a benefit from anticoagulation. These findings require validation by meta-analyses of prior studies.

  • Open Access

    E-184 Morphological characteristics of brain aneurysms among age groups

    by S Sanchez, M Essibayi, M Hickerson, D Ojeda, S Al Kasab, S Yoshimura, P Jabbour, J Mascitelli, M Levitt, H Cuellar-Saenz, et al.

    Background Age is a risk determinant in various clinical scales. Current knowledge about the morphology of ruptured aneurysms of patients of varying ages is limited. We present a multicenter study that aimed at determining age-dependent morphological characteristics of brain aneurysms. Methods Unruptured and ruptured saccular aneurysms from the STAR registry were evaluated. Our analysis consisted of location, size, neck, width, height, aspect ratio, and regular versus irregular morphology. Logistic regression was utilized to estimate the risk of rupture presentation. Results A total of 1407 unruptured and 607 ruptured aneurysms were included. The MCA and ACOM were the most common locations for ruptured aneurysms in patients younger than 70 years. Conversely, ACOM and PCOM were the most common locations for ruptured aneurysms in patients older than 70 years-old. The size of unruptured aneurysms increased among age groups (p < .001). However, size was similar among ruptured aneurysms of different age groups (p = .142). Unruptured and ruptured aneurysms became more irregular with age (p < .001 and p .025, respectively). Finally,ruptured aneurysms were more likely to be irregular in all age groups: 20-50 (OR = 3.9, 95% CI [2.0-4.7]); 51 -70 (OR = 1.9, 95% CI [1.5-2.6]); and 71-100 (OR = 3.4, 91% CI [2.2-5.4]). Conclusion The morphology of saccular brain aneurysms is different among age groups. An irregular morphology is a high-risk feature regardless of age. In younger patients, aneurysms are smaller, tend to be more regular and ruptured aneurysms are mostly located in the MCA and ACOM. In older patients, aneurysms are larger, have a more irregular morphology and ruptured aneurysms are mostly located in the PCOM and ACOM. Disclosures S. Sanchez: None. M. Essibayi: None. M. Hickerson: None. D. Ojeda: None. S. Al Kasab: None. S. Yoshimura: None. P. Jabbour: None. J. Mascitelli: None. M. Levitt: None. H. Cuellar-Saenz: None. W. Brinjikji: None. A. Spiotta: None. A. Shaban: None. E. Samaniego: None.

  • Open Access

    P-025 Aspirin decreases aneurysmal wall enhancement: a pilot study in rabbits

    by D Ojeda, S Sanchez, J Miller, L Noboa, R Kadiervel, D Hasan, E Samaniego

    Introduction Aneurysmal wall enhancement (AWE) has been correlated with inflammation of the aneurysm wall. Previous studies suggest that aspirin can decrease AWE by tapering the inflammatory cascade. We performed a pilot study using an animal model to analyze the effects of aspirin in AWE. Methods The study was designed in two phases. Induction of the aneurysm was made with elastase in the common carotid artery. During Phase I, five aneurysms were compared to five control vessels. Phase II included 6 elastase-induced aneurysms that received LPS. During phase II, 50% (3/6) of aneurysms received aspirin for 8 weeks and the rest were used as a control group. Additionally, lipopolysaccharide (LPS) was administered to some aneurysms to enhance inflammation. Aneurysmal wall enhancement (AWE) was calculated using a region of interest in MRI and was normalized to the subscapular muscle. Finally, tissue specimens of the aneurysm were stained for CD68. Results AWE was higher in induced aneurysm compared with control vessels (1.9 ± 0.4 vs 0.9 ± 0.1). Compared to aneurysms that did not receive aspirin, aneurysms treated with aspirin had thinner walls (0.57 ± 0.06mm vs 0.62 ± 0.10mm) and had less AWE at 8 weeks (2.11 ± 0.15 vs 2.15 ± 0.37). Histological analysis revealed that aneurysms that received aspirin for 8 weeks had decreased expression CD68 (figure 1). Conclusions Aneurysms that received aspirin had thinner walls and enhanced less than aneurysms not treated with aspirin. Aspirin also decreased expression of inflammatory mediators such as CD68 in the vessel wall. The normal vessel (arrowhead, A) was compared to the elastase-induced aneurysm (arrowhead, D). AWE of the aneursysms that did not receive aspirin (arrowhead, B) was higher than aneurysms treated with aspirin (arrowhead, E). The expression of CD68 (green) is mainly present in the control anesurysms (c).CD68 (green) is less expressed in anesurysm that received asiprin (F) Disclosures D. Ojeda: None. S. Sanchez: None. J. Miller: None. L. Noboa: None. R. Kadiervel: None. D. Hasan: None. E. Samaniego: None.

  • Open Access

    O-010 Tigertriever in the treatment of acute ischemic stroke in patients with underlying intracranial atherosclerotic disease

    by D Ojeda, S Sanchez, J Miller, M Almajali, P Koul, L Noboa, M Ghannam, E Samaniego

    Introduction The Tigertriver allows the operator to control the radial expansion inside the target vessel. The increased radial force of Tigertriever may provide a more effective thrombectomy in patients with acute ischemic stroke (AIS) due to intracranial atherosclerotic disease (ICAD). We analyzed data from the TIGER trial1 to determine the safety and effectiveness of Tigertriever in patients with ICAD. Methods Computed tomography angiography, and digital subtraction angiography of patients enrolled in the TIGER trial who had underlying ICAD were analyzed by a blinded core laboratory. Underlying ICAD at the large vessel occlusion was adjudicated by two independent investigators. In case of discrepancy, a third senior investigator served as adjudicator. Successful reperfusion was defined as TICI 2b-3 within three passes (figure 1). Only patients who did not require rescue therapy with other devices were included in the analysis to decrease cofounders. Results One-hundred sixty patients who were included in the TIGER trial were analyzed. Twenty percent (32/160) of patients were determined to have underlying ICAD that may have contributed to the occlusion due to stenosis or was the primary etiology for the large vessel occlusion. Twenty-three (23/32, 72%) patients with ICAD achieved successful reperfusion within 3 passes; the rest required rescue treatment with ancillary devices. Baseline NIHSS score was 16.5 (IQR=7) and median baseline ASPECT score was 9 (IQR=1). Tigetriever had a higher successful reperfusion rate within the first 3 passes (72%) compared to other studies with other stentrievers (63%-65). An increase in the proximal diameter of the occluded vessel was seen after thrombectomy (1.55 ± 0.74 versus 1.86 ± 0.7, p < 0.001). No symptomatic intracranial hemorrhages were observed while asymptomatic intracranial hemorrhage at 24 hours occurred in 17.4% (4/23) of patients. No procedural complications were reported. The NIHSS at 24-hours was 7.95 ± 7.12, and mortality rate for any cause at 3 months was 21.74% (5/23). At three months, 68% (14/23) of patients achieved a mRS score of < 2, compared to historical controls with other stentrievers (42.4% (15/36); 42% (10/24). Conclusion Tigertriever exerts a higher radial force that can be manually tailored to achieve better recanalization in patients with LVO due to ICAD. Reference Gupta R, Saver JL, Levy E, et al. New class of radially adjustable stentrievers for acute ischemic stroke: primary results of the multicenter TIGER trial. Stroke. May 2021;52(5):1534-1544. doi:10.1161/strokeaha.121.034436 (A) A right Ml occlusion due to underlying ICAD (arrowhead). (B) The Tigertriever is deployed across the stenosis. The device ‘massages’ the thrombus and exerts an increased radial force in stenotic lesions due to ICAD (arrowhead). (C) Recanalization with mild residual stenosis (arrowhead) Disclosures D. Ojeda: None. S. Sanchez: None. J. Miller: None. M. Almajali: None. P. Koul: None. L. Noboa: None. M. Ghannam: None. E. Samaniego: None.

  • 3D Enhancement Color Maps in the Characterization of Intracranial Atherosclerotic Plaques

    by S. Sanchez, A. Raghuram, R. Fakih, L. Wendt, G. Bathla, M. Hickerson, S. Ortega-Gutierrez, E. Leira, E.A. Samaniego

    BACKGROUND AND PURPOSE: High-resolution MR imaging allows the identification of culprit symptomatic plaques after the administration of gadolinium. Current high-resolution MR imaging methods are limited by 2D multiplanar views and manual sampling of ROIs. We analyzed a new 3D method to objectively quantify gadolinium plaque enhancement. MATERIALS AND METHODS: Patients with stroke due to intracranial atherosclerotic disease underwent 7T high-resolution MR imaging. 3D segmentations of the plaque and its parent vessel were generated. Signal intensity probes were automatically extended from the lumen into the plaque and the vessel wall to generate 3D enhancement color maps. Plaque gadolinium (Gd) uptake was quantified from 3D color maps as gadolinium uptake = (µPlaque T1 + Gd −µPlaque T1/SDPlaque T1). Additional metrics of enhancement such as enhancement ratio, variance, and plaque-versus-parent vessel enhancement were also calculated. Conventional 2D measures of enhancement were collected for comparison. RESULTS: Thirty-six culprit and 44 nonculprit plaques from 36 patients were analyzed. Culprit plaques had higher gadolinium uptake than nonculprit plaques (P < .001). Gadolinium uptake was the most accurate metric for identifying culprit plaques (OR, 3.9; 95% CI 2.1–8.3). Gadolinium uptake was more sensitive (86% versus 70%) and specific (71% versus 68%) in identifying culprit plaques than conventional 2D measurements. A multivariate model, including gadolinium uptake and plaque burden, identified culprit plaques with an 83% sensitivity and 86% specificity. CONCLUSIONS: The new 3D color map method of plaque-enhancement analysis is more accurate for identifying culprit plaques than conventional 2D methods. This new method generates a new set of metrics that could potentially be used to assess disease progression.


  • Open Access

    Natural history, angiographic presentation and outcomes of anterior cranial fossa dural arteriovenous fistulas

    by Sebastian Sanchez, Ashrita Raghuram, Linder Wendt, Minako Hayakawa, Ching-Jen Chen, Jason P Sheehan, Louis J Kim, Isaac Josh Abecassis, Michael R Levitt, R Michael Meyer, et al.

    Background Anterior cranial fossa dural arteriovenous fistulas (ACF-dAVFs) are aggressive vascular lesions. The pattern of venous drainage is the most important determinant of symptoms. Due to the absence of a venous sinus in the anterior cranial fossa, most ACF-dAVFs have some degree of drainage through small cortical veins. We describe the natural history, angiographic presentation and outcomes of the largest cohort of ACF-dAVFs. Methods The CONDOR consortium includes data from 12 international centers. Patients included in the study were diagnosed with an arteriovenous fistula between 1990–2017. ACF-dAVFs were selected from a cohort of 1077 arteriovenous fistulas. The presentation, angioarchitecture and treatment outcomes of ACF-dAVF were extracted and analyzed. Results 60 ACF-dAVFs were included in the analysis. Most ACF-dAVFs were symptomatic (38/60, 63%). The most common symptomatic presentation was intracranial hemorrhage (22/38, 57%). Most ACF-dAVFs drained through cortical veins (85%, 51/60), which in most instances drained into the superior sagittal sinus (63%, 32/51). The presence of cortical venous drainage predicted symptomatic presentation (OR 9.4, CI 1.98 to 69.1, p=0.01). Microsurgery was the most effective modality of treatment. 56% (19/34) of symptomatic patients who were treated had complete resolution of symptoms. Improvement of symptoms was not observed in untreated symptomatic ACF-dAVFs. Conclusion Most ACF-dAVFs have a symptomatic presentation. Drainage through cortical veins is a key angiographic feature of ACF-dAVFs that accounts for their malignant course. Microsurgery is the most effective treatment. Due to the high risk of bleeding, closure of ACF-dAVFs is indicated regardless of presentation.